| Primary |
| Drug Use For Unknown Indication |
24.1% |
| Rheumatoid Arthritis |
15.6% |
| Product Used For Unknown Indication |
11.9% |
| Diffuse Large B-cell Lymphoma |
9.0% |
| Non-hodgkin's Lymphoma |
8.6% |
| B-cell Lymphoma |
7.4% |
| Chronic Lymphocytic Leukaemia |
5.3% |
| Lymphoma |
3.4% |
| Premedication |
2.5% |
| Mantle Cell Lymphoma |
2.4% |
| Systemic Lupus Erythematosus |
2.1% |
| Prophylaxis |
1.5% |
| Hypertension |
1.2% |
| Burkitt's Lymphoma |
0.9% |
| Pain |
0.9% |
| Malignant Lymphoid Neoplasm |
0.8% |
| Idiopathic Thrombocytopenic Purpura |
0.7% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
0.6% |
| Osteoporosis |
0.6% |
| Wegener's Granulomatosis |
0.5% |
|
| Death |
15.6% |
| Progressive Multifocal Leukoencephalopathy |
13.1% |
| Pyrexia |
7.4% |
| Thrombocytopenia |
5.7% |
| Neutropenia |
5.4% |
| Pneumonia |
4.9% |
| Sepsis |
4.4% |
| Pneumocystis Jiroveci Pneumonia |
4.0% |
| Pulmonary Embolism |
4.0% |
| Disease Progression |
3.9% |
| Myocardial Infarction |
3.8% |
| Vomiting |
3.8% |
| Respiratory Failure |
3.4% |
| Febrile Neutropenia |
3.4% |
| Renal Failure |
3.3% |
| Pulmonary Fibrosis |
3.2% |
| Breast Cancer |
3.1% |
| Cerebrovascular Accident |
2.9% |
| Interstitial Lung Disease |
2.4% |
| Urinary Tract Infection |
2.4% |
|
| Secondary |
| Product Used For Unknown Indication |
15.8% |
| B-cell Lymphoma |
13.7% |
| Rheumatoid Arthritis |
13.6% |
| Drug Use For Unknown Indication |
9.1% |
| Diffuse Large B-cell Lymphoma |
8.1% |
| Non-hodgkin's Lymphoma |
7.3% |
| Chronic Lymphocytic Leukaemia |
6.5% |
| Lymphoma |
5.1% |
| Mantle Cell Lymphoma |
3.7% |
| Premedication |
3.5% |
| Systemic Lupus Erythematosus |
2.6% |
| Prophylaxis |
2.2% |
| Hypertension |
2.0% |
| Pain |
1.5% |
| Burkitt's Lymphoma |
1.5% |
| Malignant Lymphoid Neoplasm |
1.0% |
| Osteoporosis |
0.8% |
| Polymyositis |
0.8% |
| Hypothyroidism |
0.6% |
| Depression |
0.6% |
|
| Progressive Multifocal Leukoencephalopathy |
17.0% |
| Pyrexia |
10.4% |
| Thrombocytopenia |
7.9% |
| Neutropenia |
7.4% |
| Sepsis |
5.0% |
| Vomiting |
4.3% |
| Lung Adenocarcinoma |
4.1% |
| Death |
3.9% |
| Febrile Neutropenia |
3.9% |
| Myelodysplastic Syndrome |
3.7% |
| Weight Increased |
3.7% |
| Respiratory Failure |
3.5% |
| Pneumonia |
3.4% |
| Weight Decreased |
3.3% |
| Pancytopenia |
3.2% |
| Interstitial Lung Disease |
3.1% |
| White Blood Cell Count Decreased |
3.1% |
| Acute Myeloid Leukaemia |
3.0% |
| Hepatitis B |
2.9% |
| Polyneuropathy |
2.9% |
|
| Concomitant |
| Rheumatoid Arthritis |
18.2% |
| Drug Use For Unknown Indication |
16.6% |
| Product Used For Unknown Indication |
13.1% |
| Non-hodgkin's Lymphoma |
11.7% |
| B-cell Lymphoma |
5.2% |
| Chemotherapy |
4.1% |
| Lymphoma |
4.0% |
| Prophylaxis |
3.3% |
| Diffuse Large B-cell Lymphoma |
3.0% |
| Hepatitis C |
2.7% |
| Osteoporosis |
2.7% |
| Premedication |
2.1% |
| Prophylaxis Of Nausea And Vomiting |
2.1% |
| Chronic Lymphocytic Leukaemia |
1.7% |
| Hypertension |
1.7% |
| Bone Marrow Conditioning Regimen |
1.7% |
| Vitamin Supplementation |
1.7% |
| Diabetes Mellitus |
1.4% |
| Immunosuppression |
1.4% |
| Mantle Cell Lymphoma |
1.4% |
|
| Sepsis |
13.0% |
| Renal Failure |
7.5% |
| Neutropenia |
6.8% |
| Pancytopenia |
6.8% |
| Thrombocytopenia |
6.8% |
| Febrile Neutropenia |
6.2% |
| Therapeutic Response Decreased |
5.6% |
| Respiratory Failure |
5.0% |
| Leukopenia |
4.3% |
| Renal Failure Acute |
4.3% |
| Weight Decreased |
4.3% |
| Aplasia Pure Red Cell |
3.7% |
| Drug Ineffective |
3.7% |
| Myelodysplastic Syndrome |
3.1% |
| Off Label Use |
3.1% |
| Optic Neuropathy |
3.1% |
| Polyneuropathy |
3.1% |
| Pyrexia |
3.1% |
| Septic Shock |
3.1% |
| Wound |
3.1% |
|
| Interacting |
| Rheumatoid Arthritis |
34.0% |
| Drug Use For Unknown Indication |
14.6% |
| Product Used For Unknown Indication |
10.7% |
| Diffuse Large B-cell Lymphoma |
6.8% |
| B-cell Lymphoma |
5.8% |
| Chronic Lymphocytic Leukaemia |
5.8% |
| Non-hodgkin's Lymphoma |
5.8% |
| Pneumonia Bacterial |
3.9% |
| Premedication |
2.9% |
| Castleman's Disease |
1.9% |
| Prophylaxis |
1.9% |
| Chemotherapy |
1.0% |
| Hypercholesterolaemia |
1.0% |
| Hypertension |
1.0% |
| Osteoporosis |
1.0% |
| Parkinson's Disease |
1.0% |
| Prophylaxis Of Nausea And Vomiting |
1.0% |
|
| Drug Interaction |
23.8% |
| Gastrointestinal Perforation |
19.0% |
| Hepatitis Fulminant |
9.5% |
| Neutropenia |
9.5% |
| Thrombocytopenia |
9.5% |
| Iiird Nerve Paralysis |
4.8% |
| Leukopenia |
4.8% |
| Malaise |
4.8% |
| Pneumonitis |
4.8% |
| Urticaria |
4.8% |
| Venous Thrombosis |
4.8% |
|
